Skip to main content
Premium Trial:

Request an Annual Quote

Calibrant, Yale to Collaborate on Ovarian, Breast Cancer Drug ID Study

NEW YORK (GenomeWeb News) – Calibrant Biosystems today said that it will collaborate with researchers at the Yale University School of Medicine to identify ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform.
 
Gaithersburg, Md.-based Calibrant said that it would identify proteins and protein networks involved in ovarian and breast cancer and select therapeutic targets found to be central to disease progression. The firm will collaborate with Fattaneh Tavasolli, a professor of pathology and director of the Women’s Health Program/Gynecology and Breast Pathology at Yale.
 
Terms of the collaboration were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.